Applications and challenges for CRISPR/Cas9-mediated gene editing
-
Published:2022
Issue:
Volume:
Page:
-
ISSN:0094-243X
-
Container-title:7TH INTERNATIONAL CONFERENCE ON MATHEMATICS: PURE, APPLIED AND COMPUTATION: Mathematics of Quantum Computing
-
language:
-
Short-container-title:
Reference29 articles.
1. Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, Daley H, MacKinnon B, Morris E, Federico A et al: Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. New England Journal of Medicine 2020, 384(3):205–215.
2. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
3. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O’Connell D, Walsh KR, Wood K et al: CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine 2021.
4. A New Class of Medicines through DNA Editing
5. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements